According to Zhitong Finance App News, Zhaoyan New Pharmaceutical (06127) announced that in the first three quarters of 2026, the group achieved revenue of about 1,188 billion yuan, an increase of 20.6% over the previous year; net profit attributable to shareholders of listed companies was about 930 million yuan, an increase of about 10.52 times over the previous year; and basic earnings per share were 1.25 yuan.

According to the announcement, profit growth was mainly due to the dual effects of increased gross profit from the beginning of the year to the end of the reporting period and income from changes in the fair value of biological assets.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.